Capri Global Capital Limited Public Issue of NCDs Successfully Oversubscribed

Capri Global Capital Limited has successfully closed its latest public issue of secured, rated, listed, non-convertible debentures (NCDs). The offering, which ran from April 15 to April 28, 2026, saw a strong investor response across all categories. Notably, the Qualified Institutional Buyer (QIB) and corporate segments saw subscriptions exceeding 2x and 1.14x respectively, reflecting robust market confidence in the firm’s business model and growth trajectory.

Strong Investor Demand

The public issue of NCDs saw significant interest, driven by a base issue of ₹1,000 million with a green shoe option of ₹4,000 million, aggregating to a total of ₹5,000 million. The positive reception from both institutional and retail investors underscores the market’s trust in the company’s prudent risk management and sound corporate governance.

Strategic Use of Funds

The company plans to utilize at least 75% of the raised funds for onward lending, financing activities, and the repayment of interest and principal on existing borrowings. The remaining balance is earmarked for general corporate purposes, adhering to a limit of 25% of the total amount raised.

Flexible Tenure and Payout Options

Investors were offered multiple tenure choices, including 24, 36, 60, and 120 months. The NCDs feature both monthly and annual interest payout options, with competitive coupon rates of up to 9.50% per annum. This successful capital raise provides the company with increased flexibility to expand its reach and serve underbanked customers across the country.

About the Company

Capri Global Capital Limited is a well-diversified retail-focused non-banking financial company. As of March 31, 2026, the firm manages an AUM of over ₹36,000 crores and operates a network of more than 1,400 branches. The company provides a comprehensive suite of secured loan products, including MSME loans, gold loans, construction finance, and housing loans.

Source: BSE

Previous Article

Alivus Life Sciences Board Meeting Scheduled for May 14, 2026

Next Article

Vijaya Diagnostic Centre Financial Results, Dividend Declaration, and Strategic Business Acquisition